ReviewFrontiers in pharmacology2026
Interleukin-17 in disease pathogenesis and therapy: recent advances in targeted drug design and medicinal chemistry.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17 (IL-17) is a key pro-inflammatory cytokine that plays an essential role in host defense and immune regulation. Dysregulated IL-17 expression and signaling are implicated in the pathogenesis of a broad range of chronic inflammatory and autoimmune diseases, including psoriasis, systemic lupus erythematosus, periodontitis, and cancer. Increasing insights into IL-17 receptor engagement and downstream signaling networks, have established the IL-17 axis as a promising therapeutic target. Monoclonal antibodies targeting IL-17 or its receptor have demonstrated substantial clinical efficacy; however, their widespread application is limited by high cost, suboptimal tissue penetration, potential immunogenicity, and therapy-associated adverse effects. These limitations have driven growing interest in the development of alternative therapeutic strategies. This review provides a comprehensive overview of IL-17 signaling pathways and their contributions to disease pathogenesis and systematically summarizes current therapeutic approaches targeting the IL-17 axis, including monoclonal antibodies and emerging small-molecule inhibitors. Collectively, these insights offer a conceptual framework to support the rational design and development of next-generation IL-17-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.